CUMBERLAND PHARMACEUTICALS INC Cash Flow Statement
CPIX|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
CUMBERLAND PHARMACEUTICALS INC generated $5M in operating cash flow and $5M in free cash flow in FY2025. Free cash flow margin was 41.3% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $1.3M | -$6.3M | -$5.6M | -$3.5M | -$3.5M | -$3.3M | -$3.5M | -$944.7K | $731.4K | $2.4M | -$2.1M | $5.8M | $5.7M | $2.5M | $3.1M |
| Depreciation & Amortization | $4.1M | $4.9M | $5.3M | $4.6M | $4.4M | $4.7M | $4.4M | $2.4M | $2.2M | $2.0M | $1.3M | $901.6K | $1.0M | $978.4K | $816.5K |
| Operating Cash Flow | $4.9M | $6.1M | $8.5M | $6.3M | $3.1M | $5.4M | $3.1M | $569.5K | $5.9M | $6.7M | $746.1K | $7.1M | $8.7M | $346.7K | $405.0K |
| Capital Expenditures | $97.9K | $281.3K | $102.1K | $103.5K | $246.2K | $140.8K | $246.2K | $130.9K | $143.0K | $163.3K | $97.4K | $464.9K | $257.5K | $577.2K | $601.8K |
| Free Cash Flow | $4.8M | $5.8M | $8.4M | $6.2M | $2.8M | $5.3M | $2.8M | $438.6K | $5.7M | $6.5M | $648.7K | $6.7M | $8.5M | -$230.5K | -$196.8K |
| Share Buybacks | $263.5K | $740.5K | $1.1M | $1.4M | $3.5M | $1.9M | $3.5M | $2.5M | $5.3M | $4.3M | $4.8M | $8.1M | $4.2M | $4.8M | $27.3M |
| FCF Margin | 41.3% | 14.7% | 19.9% | 17.3% | 8.2% | 14.1% | 8.2% | 1.3% | 637.1% | 1088.4% | 81.1% | 952.9% | 16.6% | -0.5% | -0.4% |